Innovative Fully-Connected Continuous Manufacturing™ technology and advanced facilities are revolutionizing biomanufacturing and driving cost efficiency, especially in monoclonal antibody production.
Russell Miller
Advertisement
Articles by Russell Miller
Advertisement
Latest Updated Articles
Fully-Connected Continuous Manufacturing™ as the Key to Cost Efficiency and Scalability in BiotechPublished: April 22nd 2025 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Op-Ed: Why the US Must Move Beyond Its mRNA Monoculture
2
What a $2 Billion Maryland Expansion Means for the Future of Biologics Production
3
How New ADC Modalities Backed by Samsung Could Shape Solid Tumor Treatment
4
Formulation Strategies, Tech Advances, Challenges, and Considerations in Novel Drug Delivery
5
